United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Pharmaceutical Preparations · Silver Spring, MD
Our rating: Positive
Positive reaffirmed at $565.72, moderate conviction, November 5, 2026.
Breaks if: The Positive call weakens if reported revenue growth decelerates below 5% year-over-year for two consecutive quarterly prints — a signal that the Tyvaso DPI ramp is flattening materially earlier than the current trajectory implies — or if free cash flow margin drops below 20% (against the current ~31%) across the next two quarterly reports, indicating that capital spending has moved from strategically justified to structurally dilutive. On the other side, two consecutive quarters of revenue growth above 15% combined with FCF margin recovering toward 35% would prompt a re-evaluation toward Conviction.
Key figures
| Market value | $23.6B |
|---|---|
| Revenue, last 12 months | $3.2B |
| Net income, last 12 months | $1.2B |
| Free cash flow, last 12 months | $867M |
| Price to earnings | 19.2× |
| Free cash flow yield | 3.7% |
| Dividend yield | 0.0% |
| Operating margin | 41.4% |
| Return on equity | 19.1% |
| Beta to the S&P 500 | 0.43 |
| Volatility, annualized | 40.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $833M | 4.1% | $5.71 | $126M |
| June 30, 2026 | $783M | −1.9% | $7.27 | $206M |
| March 31, 2026 | $782M | −1.6% | $5.82 | $363M |
| December 31, 2025 | $790M | 7.4% | $7.69 | $173M |
| September 30, 2025 | $800M | 6.8% | $7.16 | $352M |
| June 30, 2025 | $799M | 11.7% | $6.41 | $130M |
| March 31, 2025 | $794M | 17.2% | $6.63 | $386M |
| December 31, 2024 | $736M | 19.7% | $6.21 | $255M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.81B: Claude 52%, Gemini 80%, Mistral 62%
- Diluted earnings per share are at least $7.69: Claude 38%, Gemini 30%, Mistral 22%
- Free cash flow for the quarter is at least $0.17B: Claude 55%, Gemini 45%, Mistral 58%
11 ledger entries and 13 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.